Pharmaceuticals

Ascletis' ASC36_35FDC Demonstrated Potential for Once-Monthly to Once-Quarterly Dosing and Robust Weight-Loss in Preclinical Studies Presented at EASD 2026

HONG KONG, Oct. 2, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announced the presentation of key preclinical data for its ASC36_35FDC (ASC36_35 co-formulation) at the 62nd European Association for the Study of Diabetes (EASD) Annual Meeting, being held September 28–Oc...

2026-10-02 17:00 1632

Lundbeck to showcase progress across its movement disorders pipeline with data in multiple system atrophy and Parkinson's disease at MDS® 2026

* Late-breaking Phase III MASCOT oral presentation will characterize the clinical profile and diversity of participants in Lundbeck's ongoing global Phase III trial investigating amlenetug in multiple system atrophy (MSA) * New research across clinical trial endpoints, biomarkers, diagnostic t...

2026-10-02 15:05 1761

Emerald Clinical Trials Appoints Michael Stibilj as Chief Executive Officer to Lead Next Phase of Global Growth

SINGAPORE, Oct. 1, 2026 /PRNewswire/ -- Emerald  Clinical Trials

2026-10-01 11:00 3521

Suvoda's latest platform release creates a global experience across study data, patient engagement, scheduling, payments, and clinical trial operations

CONSHOHOCKEN, Pa., Sept. 30, 2026 /PRNewswire/ -- Suvoda , a global clinical trial technology company, today announced a new release of important advancements since unifying the marke...

2026-09-30 22:00 1978

The 94th CMEF, the World's Leading Medical Device Industry Event, Set to Open in Beijing Oct. 21-24

BEIJING, Sept. 30, 2026 /PRNewswire/ -- The 94th China International Medical Equipment Fair (CMEF) and concurrent events—including ICMD, covering medical device design and manufacturing; CRS, focusing on rehabilitation and assistive technology; CECN, dedicated to elderly care and nursing; and Hea...

2026-09-30 21:16 989

Zhendong Pharmaceutical Announces Publication of Phase IIb Study of Investigational Vaginal Lactobacillus Capsule in the National Medical Journal of China

BEIJING, Sept. 30, 2026 /PRNewswire/ -- Zhendong Pharmaceutical announced that results from a multicenter, randomized, double-blind, placebo-controlled Phase IIb study evaluating its investigational Live Double Combined Lactobacillus Capsule for Vaginal Use for the treatmen...

2026-09-30 20:00 1090

Tamarind Health launches Rare Cancer Centre to make specialist expertise easier to access

New Rare Cancer Centre brings together expertise in rare and complex cancers, giving patients, families and referring physicians a single point of access to specialist care. SINGAPORE, Sept. 30, 2026 /PRNewswire/ -- Marking Rare Cancer Day, Tamarind Health today announced the launch of its Rare ...

2026-09-30 13:28 1261

Telix Granted FDA Fast Track Designation for BiPASS Pre-Biopsy Prostate Cancer Imaging

* FDA Fast Track designation granted for Telix's BiPASS® program, which is evaluating68Ga-PSMA-PET imaging alongside MRI in the pre-biopsy prostate cancer setting. * The designation recognizes the program's potential to address an important unmet need by enabling an imaging-first approach to ...

2026-09-30 08:26 1120

Vitaceuticals Founders Win National Manufacturing Award for Australian-Made Health Range

Pharmacists Sally Tadros and Cyndi Khawaja recognised at the 2026 Australian Women's Small Business Champion Awards. SYDNEY, Sept. 29, 2026 /PRNewswire/ -- Sydney pharmacists and sisters Sally Tadros and Cyndi Khawaja have won the Manufacturing category at the 2026 Australian Women's Small Busin...

2026-09-29 09:16 918

Ascletis Announces Positive Results from 28-Day Proof-of-Concept Clinical Study in U.S. for ASC50, a First-in-Class and Best-in-Class Oral Small Molecule IL-17A Inhibitor for the Treatment of Plaque Psoriasis

- 48.9% placebo-adjusted reduction in psoriasis area and severity index (PASI) score achieved in mild-to-moderate plaque psoriasis patients with once-daily 200 mg 28-day treatment. - Steady-state elimination half-life after 28-day treatment in patients was 6.5 days, supporting potential once-wee...

2026-09-29 08:00 1959

Link Cell Therapies Initiates Clinical Dosing with Logic-Gated CAR-T Therapy, Expands Executive Leadership, and Upsizes Series A Financing to $90 Million

– LNK001, an AND-gated CAR-T therapy targeting CAIX and ENPP3, is being evaluated in a Phase 1 study in advanced clear cell renal cell carcinoma at MD Anderson Cancer Center – – Jie D'Elia, Ph.D., joins as Chief Executive Officer and Friedrich Graf Finckenstein, M.D., as Chief Medical Officer; c...

2026-09-28 18:59 2177

Lundbeck to establish global innovation hub in Greater Boston and relocate US headquarters

* The new hub in Greater Boston will bring Lundbeck closer to one of the world's leading life sciences ecosystems, strengthening access to science, talent and partnerships. * The move is part of Lundbeck's continued investment in the US, a key market, and will support the company's Focused In...

2026-09-25 15:52 3026

Basecamp Research raises $140M to advance AI-designed therapeutics

/C O R R E C T I O N -- Basecamp Research/ In the news release, Basecamp Research raises $140M to advance AI-designed therapeutics, issued 23-Sep-2026 by Basecamp Research over PR Newswire, we are advised by the company that information has changed in the first bulleted subheadline and in the fo...

2026-09-25 01:44 2357

Daewoong Pharmaceutical Presents Baseline Characteristics of 104 Patients in Global Phase 2 Trial for IPF Drug Candidate 'Bersiporocin' at ERS 2026

* 104 IPF patients enrolled in US and South Korea as global Phase 2 trial progresses toward completion * Study includes both antifibrotic-treated and untreated patients; top-line data expected in H1 2027 * First-in-class PRS inhibitor being developed as a potential new therapeutic option...

2026-09-24 08:00 2572

Basecamp Research raises $140M to advance AI-designed therapeutics

* Oversubscribed Series C led by S32 with backing from NVIDIA and others * Funding will advance a pipeline of EDEN-designed therapeutics, starting with in vivo cell therapy, and expand pharmaceutical partnerships * The company has demonstrated strong preclinical results across multiple modal...

2026-09-23 21:00 1073

Werfen Announces US FDA 510(k) Clearance and CE Mark for Aptiva® Antiphospholipid Syndrome IgA Reagent

FDA Clearance and CE Mark Complete Aptiva's Antiphospholipid Syndrome Portfolio, Expanding Global Access to Comprehensive APS Testing SAN DIEGO, Sept. 23, 2026 /PRNewswire/ -- Werfen today announced that its Aptiva Antiphospholipid Syndrome (APS) Immunoglobulin A (IgA) Reagent has received both ...

2026-09-23 20:00 1406

HKSH Medical Group and United Imaging Mark Launch of Hong Kong's First Long-Axial PET/CT

HONG KONG, Sept. 23, 2026 /PRNewswire/ -- HKSH Medical Group (HKSH) and United Imaging Healthcare (United Imaging) announced on September 23 the arrival of Hong Kong's first long-axial PET/CT, the uMI Panorama GS, at HKSH Cancer Centre, providing a new technology platform for molecular imaging cl...

2026-09-23 18:30 1113

Novo receives Singapore approval for Wegovy® as first treatment for MASH with liver fibrosis

ESSENCE trial data showed 63% of participants receiving semaglutide achieved steatohepatitis resolution without worsening of liver fibrosis, compared with 34% receiving placebo, at Week 72. * Singapore's Health Sciences Authority (HSA) has approved Wegovy® (once-weekly injectable semaglutide 2...

2026-09-23 10:05 2849

Kazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure Disorders

Clinical Milestone Expands Development of Paxalisib Beyond Oncology and Triggers $2 Million Payment to Kazia SYDNEY, Sept. 22, 2026 /PRNewswire/ -- Kazia Therapeutics Limited

2026-09-22 19:30 2108

Multiple Sacituzumab Tirumotecan (sac-TMT) Studies Selected as LBAs at ESMO 2026, OptiTROP-Lung04 and OptiTROP-Lung06 to be Presented in the Lung Cancer Session

CHENGDU, China, Sept. 22, 2026 /PRNewswire/ -- The 2026 European Society for Medical Oncology (ESMO) Congress will be held in Madrid, Spain, from October 23 to 27. Multiple Phase III clinical studies of the TROP2 ADC sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870) (佳泰莱®) developed...

2026-09-22 15:48 1380
12345 ... 184

Week's Top Stories